MET and glioblastoma: In order to characterize the effects of RTK inhibition upon cell motility, we performed wound healing assays in primary glioblastoma cells derived from a patient sample (p01) treated with a panel of small-molecule TKIs: EGFR inhibitor erlotinib [31], PDGFR, VEGFR, Kit and FLT3 multitargeted inhibitor sunitinib [32] and c-Met/HGFR inhibitor SU11274 [33].